According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the Phase Ib clinical trial (JMT206-003) of the jMT206 injection developed by the group for weight management in overweight or obese adult patients has been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.